News: Latest News

Read the latest news and select stories on Code Bio’s work below. 
November 14, 2022

Code Biotherapeutics Names Alex S. Tracy, PhD, as Chief Technical Officer

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering the targeted delivery of precision genetic medicines, today announces the appointment of Alex Tracy, PhD, as Chief Technical Officer.

September 28, 2022

Code Biotherapeutics Names David Anderson, PhD, as Chief Scientific Officer

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Scientific Officer.

June 7, 2022

Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.

February 22, 2022

Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.

December 2, 2021

Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer

Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the appointment of Erin Brubaker as Chief Operating Officer, effective immediately.

April 20, 2021

Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases

Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases, launches today with $10 million in financing and headquarters in the Philadelphia region’s leading gene therapy epicenter.

April 16, 2021

Code Biotherapeutics Appoints Lauren M. Kaskiel, MBA as Chief Business Officer

Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and genetic diseases, announces today that Lauren M. Kaskiel, MBA will join the company as its Chief Business Officer.